BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20307026)

  • 21. Screening for prostate cancer.
    Postma R; Schröder FH
    Eur J Cancer; 2005 Apr; 41(6):825-33. PubMed ID: 15808952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
    Klotz L
    Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
    Efstathiou JA; Chen MH; Catalona WJ; McLeod DG; Carroll PR; Moul JW; Roehl KA; D'Amico AV
    Urology; 2006 Aug; 68(2):342-7. PubMed ID: 16904449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ten year trend in prostate cancer screening with high prostate-specific antigen exposure rate in Japan.
    Okihara K; Kitamura K; Okada K; Mikami K; Ukimura O; Miki T
    Int J Urol; 2008 Feb; 15(2):156-60; discussion 161. PubMed ID: 18269453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
    Palma D; Tyldesley S; Pickles T;
    Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
    BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early outcomes of active surveillance for localized prostate cancer.
    Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
    BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
    D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
    J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Advancements in PSA-based screening for prostate cancer].
    Ito K
    Rinsho Byori; 2004 Jul; 52(7):611-7. PubMed ID: 15344561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate-specific antigen testing to screen for prostate cancer.
    Budenholzer BR
    J Fam Pract; 1995 Sep; 41(3):270-8. PubMed ID: 7544400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of clinically significant prostate cancer by prostate-specific antigen screening.
    Smith RP; Malkowicz SB; Whittington R; VanArsdalen K; Tochner Z; Wein AJ
    Arch Intern Med; 2004 Jun; 164(11):1227-30. PubMed ID: 15197049
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of prostate-specific antigen as a screening test for prostate cancer.
    Dorr VJ; Williamson SK; Stephens RL
    Arch Intern Med; 1993 Nov; 153(22):2529-37. PubMed ID: 7694555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
    Johansson E; Bill-Axelson A; Holmberg L; Onelöv E; Johansson JE; Steineck G;
    Eur Urol; 2009 Feb; 55(2):422-30. PubMed ID: 18783877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening for prostate cancer: who and how often?
    Schwartz K; Deschere B; Xu J
    J Fam Pract; 2005 Jul; 54(7):586-96. PubMed ID: 16009085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer update: 2007.
    Lin AM; Small EJ
    Curr Opin Oncol; 2008 May; 20(3):294-9. PubMed ID: 18391629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening and hormonal therapy of localized prostate cancer shows major benefits on survival.
    Labrie F
    Cancer J; 2000 Apr; 6 Suppl 2():S182-7. PubMed ID: 10803834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. "Just Another Statistic".
    Machtay M; Glatstein E
    Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rural residence and prostate cancer screening with prostate-specific antigen.
    Stamatiou K; Skolarikos A
    Rural Remote Health; 2009; 9(2):1227. PubMed ID: 19594290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.